CRCM  Vol.4 No.1 , January 2015
Keratotic and Pigmented Basal Cell Carcinoma
ABSTRACT
Background: Basal cell carcinomas or rodent ulcers are commonly seen in the tear zone of the face. It rarely mimics melanomas when pigmented. Aim: We review literature of this uncommon condition and discuss the therapeutic modalities. Case Report: An elderly lady sought attention for a pigmented lesion on her forehead. The case is presented because pigmented lesions and verrucous appearing lesions can also be due to basal cell carcinoma. Typically basal cell carcinoma appears in the tear zone of the face and it mostly affects sun exposed areas. Conclusion: While surgery remains the gold standard in treatment, other modalities can be offered in areas where vital structures cannot be sacrificed and in recurrent lesions.

Cite this paper
Rekha, A. , Parimuthukumar, R. , Pratap, A. , Leo, J. and Pai, V. (2015) Keratotic and Pigmented Basal Cell Carcinoma. Case Reports in Clinical Medicine, 4, 19-22. doi: 10.4236/crcm.2015.41005.
References
[1]   Patterson, J.W. and Wick, M.R. (2006) Nonmelanocytic Tumors of the Skin. In: Atlas of Tumor Pathology, Series 4, Fascicle 4, Armed Forces Institute of Pathology, Washington DC, 46-68.

[2]   Saldanha, G., Fletcher, A. and Slater, D.N. (2003) Basal Cell Carcinoma: A Dermatopathological and Molecular Biological Update. British Journal of Dermatology, 148, 195-202.
http://dx.doi.org/10.1046/j.1365-2133.2003.05151.x

[3]   Barry, J., Oon, S.F., Watson, R. and Barnes, L. (2006) The Management of Basal Cell Carcinomas. Irish Medical Journal, 99, 179-181.

[4]   Love, W.E., Bernhard, J.D. and Bordeaux, J.S. (2009) Topical Imiquimod or Fluorouracil Therapy for Basal and Squamous Cell Carcinoma: A Systematic Review. Archives of Dermatology, 145, 1431-1438.
http://dx.doi.org/10.1001/archdermatol.2009.291

[5]   Geisse, J., Caro, I., Lindholm, J., Golitz, L., Stampone, P. and Owens, M. (2004) Imiquimod 5% Cream for the Treatment of Superficial Basal Cell Carcinoma: Results from Two Phase III, Randomized, Vehicle-Controlled Studies. Journal of the American Academy of Dermatology, 50, 722-733.
http://dx.doi.org/10.1016/j.jaad.2003.11.066

[6]   Greenway, H.T., Cornell, R.C., Tanner, D.J., Peets, E., Bordin, G.M. and Nagi, C. (1986) Treatment of Basal Cell Carcinoma with Intralesional Interferon. Journal of the American Academy of Dermatology, 15, 437-443.
http://dx.doi.org/10.1016/S0190-9622(86)70192-8

[7]   Bale, A.E. and Yu, K.P. (2001) The Hedgehog Pathway and Basal Cell Carcinomas. Human Molecular Genetics, 10, 757-762. http://dx.doi.org/10.1093/hmg/10.7.757

[8]   Von Hoff, D.D., LoRusso, P.M., Rudin, C.M., Reddy, J.C., Yauch, R.L., Tibes, R., et al. (2009) Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma. The New England Journal of Medicine, 361, 1164-1172.
http://dx.doi.org/10.1056/NEJMoa0905360

[9]   Berman, B. (2008) Scientific Rationale: Combining Imiquimod and Surgical Treatments for Basal Cell Carcinomas. Journal of Drugs in Dermatology, 7, s3-s6.

[10]   Dandurand, M., Petit, T., Martel, P. and Guillot, B. (2006) Management of Basal Cell Carcinoma in Adults Clinical Practice Guidelines. European Journal of Dermatology, 16, 394-401.

[11]   National Comprehensive Cancer Network (2011) NCCN Clinical Practice Guidelines in Oncology. Basal Cell and Squamous Cell Skin Cancers, 1. http://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf

 
 
Top